Integrated BioPharma, Inc. Posts Financial Results for Q1 2025

Integrated BioPharma, Inc. released its financial report for the quarter ending March 31, 2025. The company recorded a revenue of $13.9 million, marking a 6.1% increase from $13.1 million during the same period in 2024. Operating income also improved, reaching $0.7 million compared to $0.4 million in the previous year.

Over the nine-month period leading to March 31, 2025, total revenue was $40.2 million, a 6.9% rise from $37.6 million the year before. Operating income surged to $1.4 million from an $0.2 million loss recorded for the same period in 2024. Net income for Q1 2025 stood at $0.6 million, doubling the $0.3 million of Q1 2024.

The growth is attributed to increased revenue from key customers in the Contract Manufacturing Segment, which contributed significantly to the company's earnings. Co-CEOs Riva Sheppard and Christina Kay highlighted the expansion of their customer base over the past year as pivotal to this financial improvement.